7-Hydroxypyrrolo[2,3-d]pyrimidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: 7-Hydroxypyrrolo[2,3-d]pyrimidine
• 化学式: C₆H₅N₃O
• 分子量: 135.12
• InChiKey: KSOZXBMWRIJMQD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  50.9
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] OPTICAL RESOLUTION OF (1-BENZYL-4-METHYLPIPERIDIN-3-YL) -METHYLAMINE AND THE USE THEREOF FOR THE PREPARATION OF PYRROLO 2,3-PYRIMIDINE DERIVATIVES AS PROTEIN KINASES INHIBITORS<br/>[FR] RESOLUTION OPTIQUE DE (1-BENZYL-4-METHYLPIPERIDINE-3-YLE) METHYLAMINE ET SON UTILISATION POUR LA PREPARATION DE DERIVES DE PYRROLO 2,3-PYRIMIDINE UTILISES COMME INHIBITEURS DE PROTEINES KINASE
  申请人：PFIZER PROD INC

  公开号：WO2002096909A1

  公开（公告）日：2002-12-05

  A method for resolving enantiomers of a compound containing the structure of the formula (I): wherein R4 or R5 may contain one or more asymmetric centers, by mixing a racemic mixture of enantiomers of a compound, containing the structure of said formula; in a solvent, with a resolving compound having a defined stereospecificity, to form a solution and with said resolving agent being capable of binding with at least one but not all of said enantiomers to form a precipitate, containing said at least one of said enantiomers in stereospecific form and collecting either the precipitate and purifying it or collecting the solution with contained other of said enantiomers and recrystalizing the enantiomer contained in said solution.

  一种用于分离含有公式（I）结构的化合物的对映异构体的方法，其中R4或R5可能包含一个或多个不对称中心，通过将含有该公式结构的化合物的对映异构体的混合物与一个具有定义的立体特异性的分离剂混合在溶剂中，形成溶液，所述分离剂能够与至少一个但不是全部的对映异构体结合形成沉淀，其中包含所述至少一个对映异构体的立体特异形式，并收集沉淀并纯化它，或收集所述溶液并重新结晶所述溶液中所含的其他对映异构体并分离所述溶液中所含的所述对映异构体。
• [EN] PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS<br/>[FR] PYRROLOPYRIMIDINES UTILISEES COMME INHIBITEURS DE PROTEINES KINASES
  申请人：BASF AG

  公开号：WO2000017203A1

  公开（公告）日：2000-03-30

  Chemical compounds having structural formula (I) and physiologically acceptable salts and metabolites thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases, whose activity is inhibited by these chemical compounds, are involved in immunologic, hyperproliferative, or angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyper proliferative disorders, rheumatoid arthritis, disorders of the immune system, transplant rejections and imflammatory disorders.

  具有结构式（I）和生理上可接受的盐及其代谢物的化合物是丝氨酸/苏氨酸和酪氨酸激酶活性的抑制剂。这些化合物抑制的多种激酶参与免疫、过度增殖或血管生成过程。因此，这些化合物可以改善与血管生成或内皮细胞过度增殖有关的疾病状态。这些化合物可用于治疗癌症和过度增殖性疾病、类风湿性关节炎、免疫系统紊乱、移植排斥和炎症性疾病。
• 3-((3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidinyl)-3-oxo-propionitrile as protein kinase inhibitor
  申请人：Pfizer Products Inc.

  公开号：EP1666481B9

  公开（公告）日：2013-05-01
• Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine
  申请人：Pfizer Products Inc.

  公开号：EP1609781B1

  公开（公告）日：2011-08-10
• OPTICAL RESOLUTION OF (1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE AND THE USE THEREOF FOR THE PREPARATION OF PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS PROTEIN KINASES INHIBITORS
  申请人：Pfizer Products Inc.

  公开号：EP1392694A1

  公开（公告）日：2004-03-03